ALRN: Aileron Therapeutics Inc Price-to-Revenue Multiple

Symbol and logo of brand Aileron (ALRN)

Aileron Therapeutics (ALRN) aims to capture the niche of exclusive chemoprotectors, outpacing competitors through the uniqueness of its mechanisms. Financial stability depends on clinical trial outcomes, with positive FCF expected following the FDA verdict. The GURU.Markets portal features a P/S ratio chart for the company, where the value represents the current metric. An innovative approach to cell protection during therapy strengthens the brand's reputation among oncologists.

ALRN Aileron Therapeutics Market Cap to Revenue (07/04/2022 - 11/15/2026)

Analytical breakdowns for Aileron (ALRN)

- share price and consensus valuation forecast:
Price Performance Chart Aileron Therapeutics, Inc.|ALRN - Analyst Consensus Forecast
- market capitalization information:
Market Capitalization ALRN|ALRN - Enterprise Value
- book capitalization data:
Net Asset Value per Share Aileron Therapeutics|ALRN - Company Net Assets|Market Cap to Book Value Multiple aileronrx.com|ALRN - Company Total Assets
- debt obligations and liquidity statistics:
Debt to Capital Aileron Therapeutics|ALRN - Long-Term Debt to Capital|Short-Term Debt to Capital Ratio Aileron|ALRN - Company Total Debt|Debt to Net Assets Ratio Aileron Therapeutics, Inc.|ALRN - Company Long-Term Liabilities|Amount of Current Liabilities Aileron Therapeutics|Intermediate Coverage Ratio aileronrx.com
- earnings and multiples data:
ALRN - Net Profit|Expected Net Profit Aileron Therapeutics|ALRN - Price to Earnings Ratio|Future Price to Earnings Multiple Aileron Therapeutics, Inc.|ALRN - PEG Multiple|EV/EBITDA Multiple Aileron Therapeutics|ALRN - Profit before payment of interest, taxes and amortization|Earnings per one share for the last 12 months Aileron Therapeutics|ALRN - Net earnings per share for the last 12 months|Earnings per share growth in annualized terms for the last twelve months aileronrx.com|ALRN - Earnings growth in current year|Earnings growth forecast for next year Aileron Therapeutics
- sales revenue and business income indicators:
ALRN - Revenue and Sales Volume|Company Future Sales Aileron Therapeutics Inc|ALRN - Price-to-Revenue Ratio|Price-to-Projected Revenue Ratio ALRN|ALRN - Sales Growth YoY (TTM)
Summary company analytics:aileronrx.com, ALRN
Mass-produced product of Aileron Therapeutics Inc

Steady demand for innovative drugs from Aileron Therapeutics (ALRN) makes the price-to-sales ratio a key indicator for valuing the business relative to its operating revenues. This ratio determines the market premium on sales, where undervalued levels signal an underpriced asset, while excessively high values create correction risks if ambitious revenue forecasts are not met.

Who Aileron Therapeutics competes with

GMAB (Genmab) - Market Capitalization-to-Revenue Ratio|P/S Multiple EXEL (Exelixis Inc)|Price-to-Revenue Multiple Nuvalent Corp|Kymera Therapeutics, Inc. - P/S Multiple|Price to Sales IDEAYA Biosciences, Inc.|ELVN (Enliven Therapeutics) - Market Cap to Revenue|ORIC: Market Cap to Sales Volume|RLAY (relaytx.com) - P/S Multiple|Price to Sales Nurix Pharma NRIX|P/S Multiple TYRA|Verastem - Market Cap to Revenue Ratio|Monte Rosa Therapeutics, Inc. - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio CGEM|IMRX: Market Cap to Revenue|C4 Tx - Market Cap to Sales Volume|BDTX: P/S Multiple|Repare Therapeutics - Market Capitalization-to-Revenue Ratio|PMVP (PMV Pharmaceuticals, Inc) - P/S Multiple|Price to Sales karyopharm.com KPTI|Price-to-Revenue Ratio Propanc Biopharma Inc. (PPCB)|BGMS (Cyclacel Pharmaceuticals) - Market Capitalization-to-Revenue Ratio|P/S Multiple AADI (Aadi Bioscience Inc)|P/S Multiple Blueprint Medicines BPMC|GLYC - Price-to-Revenue Ratio|Price-to-Sales Ratio SWTX